Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Burkitt Lymphoma 19Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Leukemia 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Recurrence 1Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cytarabine 2pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Vincristine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Mercaptopurine 1Idarubicin 1Hydrocortisone 1Etoposide 1Dexamethasone 1Daunorubicin 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Down Syndrome × blinatumomab × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡